Tempus AI, Inc. (NASDAQ:TEM) CEO Sells $4,580,221.32 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky sold 85,788 shares of the business’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $53.39, for a total transaction of $4,580,221.32. Following the transaction, the chief executive officer now directly owns 5,771,787 shares in the company, valued at approximately $308,155,707.93. The trade was a 1.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Tempus AI Stock Performance

Shares of TEM traded down $3.44 during mid-day trading on Friday, hitting $51.40. 12,994,864 shares of the company’s stock were exchanged, compared to its average volume of 9,294,415. The stock’s 50-day moving average is $44.38 and its 200-day moving average is $47.46. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $79.49.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on TEM. Bank of America increased their price target on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Piper Sandler reiterated a “neutral” rating and issued a $70.00 price objective (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and lifted their target price for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Guggenheim started coverage on Tempus AI in a report on Monday, December 9th. They set a “buy” rating and a $74.00 price target for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $56.00 price objective on shares of Tempus AI in a report on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $56.36.

Institutional Investors Weigh In On Tempus AI

A number of hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP purchased a new position in shares of Tempus AI in the 2nd quarter valued at about $4,861,000. Fred Alger Management LLC acquired a new stake in shares of Tempus AI in the 2nd quarter valued at $2,167,000. Squarepoint Ops LLC acquired a new stake in shares of Tempus AI in the 2nd quarter valued at $633,000. Employees Retirement System of Texas purchased a new stake in shares of Tempus AI during the 2nd quarter worth $1,039,000. Finally, Dragoneer Investment Group LLC acquired a new position in shares of Tempus AI during the second quarter worth $1,750,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.